Quest Diagnostics Past Earnings Performance
Past criteria checks 3/6
Quest Diagnostics's earnings have been declining at an average annual rate of -5.7%, while the Healthcare industry saw earnings growing at 17% annually. Revenues have been growing at an average rate of 3.1% per year. Quest Diagnostics's return on equity is 12.9%, and it has net margins of 8.8%.
Key information
-5.7%
Earnings growth rate
-1.8%
EPS growth rate
| Healthcare Industry Growth | 11.6% |
| Revenue growth rate | 3.1% |
| Return on equity | 12.9% |
| Net Margin | 8.8% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Quest Diagnostics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 9,539 | 838 | 1,681 | 0 |
| 30 Jun 24 | 9,346 | 836 | 1,624 | 0 |
| 31 Mar 24 | 9,287 | 842 | 1,621 | 0 |
| 31 Dec 23 | 9,252 | 850 | 1,615 | 0 |
| 30 Sep 23 | 9,297 | 759 | 1,748 | 0 |
| 30 Jun 23 | 9,488 | 790 | 1,825 | 0 |
| 31 Mar 23 | 9,603 | 789 | 1,832 | 0 |
| 31 Dec 22 | 9,883 | 942 | 1,818 | 0 |
| 30 Sep 22 | 10,294 | 1,230 | 1,736 | 0 |
| 30 Jun 22 | 10,582 | 1,479 | 1,705 | 0 |
| 31 Mar 22 | 10,679 | 1,874 | 1,715 | 0 |
| 31 Dec 21 | 10,788 | 1,988 | 1,723 | 0 |
| 30 Sep 21 | 11,046 | 2,175 | 1,674 | 0 |
| 30 Jun 21 | 11,058 | 2,238 | 1,642 | 0 |
| 31 Mar 21 | 10,335 | 1,794 | 1,571 | 0 |
| 31 Dec 20 | 9,437 | 1,425 | 1,545 | 0 |
| 30 Sep 20 | 8,361 | 1,101 | 1,414 | 0 |
| 30 Jun 20 | 7,531 | 749 | 1,378 | 0 |
| 31 Mar 20 | 7,657 | 771 | 1,376 | 0 |
| 31 Dec 19 | 7,726 | 835 | 1,457 | 0 |
| 30 Sep 19 | 7,639 | 709 | 1,402 | 0 |
| 30 Jun 19 | 7,572 | 707 | 1,406 | 0 |
| 31 Mar 19 | 7,538 | 720 | 1,387 | 0 |
| 31 Dec 18 | 7,531 | 733 | 1,395 | 0 |
| 30 Sep 18 | 7,557 | 860 | 1,378 | 0 |
| 30 Jun 18 | 7,524 | 808 | 1,359 | 0 |
| 31 Mar 18 | 7,469 | 782 | 1,372 | 0 |
| 31 Dec 17 | 7,402 | 769 | 1,421 | 0 |
| 30 Sep 17 | 7,398 | 671 | 1,413 | 0 |
| 30 Jun 17 | 7,427 | 701 | 1,480 | 0 |
| 31 Mar 17 | 7,469 | 702 | 1,558 | 0 |
| 31 Dec 16 | 7,214 | 642 | 1,337 | 0 |
| 30 Sep 16 | 7,503 | 675 | 1,624 | 0 |
| 30 Jun 16 | 7,498 | 825 | 1,637 | 0 |
| 31 Mar 16 | 7,517 | 748 | 1,637 | 0 |
| 31 Dec 15 | 7,493 | 706 | 1,616 | 0 |
| 30 Sep 15 | 7,527 | 703 | 1,654 | 0 |
| 30 Jun 15 | 7,551 | 491 | 1,657 | 0 |
| 31 Mar 15 | 7,528 | 507 | 1,651 | 0 |
| 31 Dec 14 | 7,435 | 549 | 1,635 | 0 |
| 30 Sep 14 | 7,308 | 506 | 1,638 | 0 |
| 30 Jun 14 | 7,192 | 780 | 1,620 | 0 |
| 31 Mar 14 | 7,105 | 799 | 1,620 | 0 |
| 31 Dec 13 | 7,146 | 811 | 1,632 | 0 |
Quality Earnings: Q1UE34 has high quality earnings.
Growing Profit Margin: Q1UE34's current net profit margins (8.8%) are higher than last year (8.2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Q1UE34's earnings have declined by 5.7% per year over the past 5 years.
Accelerating Growth: Q1UE34's earnings growth over the past year (10.4%) exceeds its 5-year average (-5.7% per year).
Earnings vs Industry: Q1UE34 earnings growth over the past year (10.4%) did not outperform the Healthcare industry 67.7%.
Return on Equity
High ROE: Q1UE34's Return on Equity (12.9%) is considered low.